Patent application number | Description | Published |
20110195895 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 08-11-2011 |
20140302037 | BISPECIFIC-Fc MOLECULES - Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules. | 10-09-2014 |
20140308285 | HETERODIMERIC BISPECIFIC ANTIBODIES - Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety. | 10-16-2014 |
20140356358 | VARIANT FC-POLYPEPTIDES WITH ENHANCED BINDING TO THE NEONATAL FC RECEPTOR - Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides. | 12-04-2014 |
Patent application number | Description | Published |
20090305986 | FGF21 Mutants and uses thereof - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 12-10-2009 |
20100168020 | STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF - The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided. | 07-01-2010 |
20100285131 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 11-11-2010 |
20120003216 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 01-05-2012 |
20120087920 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 04-12-2012 |
20120093815 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 04-19-2012 |
20120177646 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 07-12-2012 |
20120178685 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 07-12-2012 |
20120213779 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 08-23-2012 |
20130129725 | HUMAN FGF RECEPTOR AND BETA-KLOTHO BINDING PROTEINS - The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions. | 05-23-2013 |
20130225484 | STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF - The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided. | 08-29-2013 |
20140243503 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 08-28-2014 |
Patent application number | Description | Published |
20090103050 | OPTICAL INSTRUMENT ALIGNMENT SYSTEM - An ophthalmic apparatus for precisely positioning an optical instrument, such as a wavefront aberrometer, in three dimensions with respect to a patient's eye. The ophthalmic apparatus may include an optical instrument directed in a first direction toward a target area to receive light therefrom and a camera directed in a second direction toward the target area to receive light therefrom, the first and second directions being non-parallel. The camera may include imaging optics to form an optical image on a photodetector array using light reflected from the target area. The ophthalmic apparatus may also include a processor configured to correlate a position of the optical image on the photodetector array with the distance between the optical instrument and the target area. | 04-23-2009 |
20100152847 | OPTICAL ANGULAR MEASUREMENT SYSTEM FOR OPHTHALMIC APPLICATIONS AND METHOD FOR POSITIONING OF A TORIC INTRAOCULAR LENS WITH INCREASED ACCURACY - An ophthalmic system for use in performing angular measurements in relation to a patient's eye. The ophthalmic system can include an optical angular measurement device that can provide angular indicia by, for example, projecting an image of an angular measurement reticle onto a patient's eye or by superimposing an image of an angular measurement reticle onto an image of the patient's eye. The ophthalmic system can include an optical refractive power measurement device for providing desired angular orientations for ocular implants or for incisions. The ophthalmic system can be used, for example, to align a toric intraocular lens to a desired angular orientation. | 06-17-2010 |
20110013141 | OPHTHALMIC SURGERY MEASUREMENT SYSTEM - An ophthalmic apparatus for measuring spatial distances within a patient's eye is disclosed. The apparatus can be used to measure, for example, the capsular bag depth in an aphakic eye. The spatial measurement system can direct laser light into a patient's eye so that a portion of the light is scattered by the capsular bag. The scattered light can be directed to a detector where spots can be formed corresponding to the locations on the capsular bag from which the light was scattered. The distance from the cornea to the capsular bag can be determined based, for example, at least in part on the distance between the spots formed on the detector. In some embodiments, the apparatus can include a surgical microscope and/or a wavefront aberrometer. In some embodiments, an alignment system can be used to precisely position the apparatus relative to the patient's eye. The ophthalmic apparatus can be used for variety of ophthalmic procedures, such as predicting the postoperative position of an intraocular lens (IOL) and determining appropriate optical power for the IOL. | 01-20-2011 |
20130070203 | OPTICAL INSTRUMENT ALIGNMENT SYSTEM - An ophthalmic apparatus for precisely positioning an optical instrument, such as a wavefront aberrometer, in three dimensions with respect to a patient's eye. The ophthalmic apparatus may include an optical instrument directed in a first direction toward a target area to receive light therefrom and a camera directed in a second direction toward the target area to receive light therefrom, the first and second directions being non-parallel. The camera may include imaging optics to form an optical image on a photodetector array using light reflected from the target area. The ophthalmic apparatus may also include a processor configured to correlate a position of the optical image on the photodetector array with the distance between the optical instrument and the target area. | 03-21-2013 |
20130258462 | STEREOSCOPIC OPTICS - An adapter system for displaying and recording stereoscopic images from a single lens optic device and methods of producing stereoscopic images using such an adapter are provided herein. The adapter system utilizes an active stereoscopic shutter mounted along the optical path of the single lens optic device, such as, for example, a microscope or an endoscope, to provide a stereoscopic image to a video or still camera mounted along the same optical path. | 10-03-2013 |
20130307939 | STEREOSCOPIC RELAY OPTICS - A relay optic adapter system for imaging stereoscopic images with a single lens optic device and methods of producing stereoscopic images using such a relay optic adapter are provided herein. The relay optic adapter system utilizes an active stereoscopic shutter mounted along the optical path of the single lens optic device, such as, for example, a still or video camera, to provide a stereoscopic image to imaging plane of the device. | 11-21-2013 |
20140085604 | GEOMETRIC OPTICAL POWER MEASUREMENT DEVICE - An ophthalmic optical power measurement device can include a light source configured to direct an input beam of light into the eye of a patient. The ophthalmic optical power measurement device can also include an aperture configured to receive an output beam that consists of light from the input beam that scatters from a location on the retina of the eye and exits through the pupil of the eye. The ophthalmic optical power measurement device can also include a detector configured to receive the output beam after it has passed through the aperture. A processor can be configured to determine the size of a spot created by the output beam on the detector, and to determine the optical power of the eye based upon the size of the spot. | 03-27-2014 |
20140132922 | OPTICAL ANGULAR MEASUREMENT SYSTEM FOR OPHTHALMIC APPLICATIONS AND METHOD FOR POSITIONING OF A TORIC INTRAOCULAR LENS WITH INCREASED ACCURACY - An ophthalmic system for use in performing angular measurements in relation to a patient's eye. The ophthalmic system can include an optical angular measurement device that can provide angular indicia by, for example, projecting an image of an angular measurement reticle onto a patient's eye or by superimposing an image of an angular measurement reticle onto an image of the patient's eye. The ophthalmic system can include an optical refractive power measurement device for providing desired angular orientations for ocular implants or for incisions. The ophthalmic system can be used, for example, to align a toric intraocular lens to a desired angular orientation. | 05-15-2014 |
20140132931 | OPHTHALMIC SURGERY MEASUREMENT SYSTEM - An ophthalmic apparatus for measuring spatial distances within a patient's eye is disclosed. The apparatus can be used to measure, for example, the capsular bag depth in an aphakic eye. The spatial measurement system can direct laser light into a patient's eye so that a portion of the light is scattered by the capsular bag. The scattered light can be directed to a detector where spots can be formed corresponding to the locations on the capsular bag from which the light was scattered. The distance from the cornea to the capsular bag can be determined based, for example, at least in part on the distance between the spots formed on the detector. In some embodiments, the apparatus can include a surgical microscope and/or a wavefront aberrometer. In some embodiments, an alignment system can be used to precisely position the apparatus relative to the patient's eye. The ophthalmic apparatus can be used for variety of ophthalmic procedures, such as predicting the postoperative position of an intraocular lens (IOL) and determining appropriate optical power for the IOL. | 05-15-2014 |
20150257642 | GEOMETRIC OPTICAL POWER MEASUREMENT DEVICE - An ophthalmic optical power measurement device can include a light source configured to direct an input beam of light into the eye of a patient. The ophthalmic optical power measurement device can also include an aperture configured to receive an output beam that consists of light from the input beam that scatters from a location on the retina of the eye and exits through the pupil of the eye. The ophthalmic optical power measurement device can also include a detector configured to receive the output beam after it has passed through the aperture. A processor can be configured to determine the size of a spot created by the output beam on the detector, and to determine the optical power of the eye based upon the size of the spot. | 09-17-2015 |